Amgen (NASDAQ:AMGN) Price Target Raised to $452.00

Amgen (NASDAQ:AMGN) had its price target increased by TD Cowen from $420.00 to $452.00 in a report issued on Wednesday,Benzinga reports. The brokerage currently has a buy rating on the medical research company’s stock.

Other analysts have also recently issued reports about the company. BMO Capital Markets boosted their price target on Amgen from $400.00 to $450.00 and gave the stock an “outperform” rating in a research report on Wednesday. Barclays lifted their price objective on Amgen from $350.00 to $360.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 29th. Erste Group Bank reissued a “hold” rating on shares of Amgen in a report on Tuesday, May 5th. Robert W. Baird increased their target price on Amgen from $215.00 to $230.00 and gave the stock an “underperform” rating in a research note on Wednesday. Finally, Wall Street Zen downgraded Amgen from a “buy” rating to a “hold” rating in a report on Saturday, June 27th. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, fifteen have given a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat, Amgen presently has an average rating of “Hold” and an average price target of $370.07.

Amgen Stock Up 1.5%

NASDAQ:AMGN opened at $410.95 on Wednesday. The company has a debt-to-equity ratio of 4.44, a current ratio of 1.37 and a quick ratio of 1.01. The firm’s 50-day moving average price is $362.77 and its 200-day moving average price is $356.24. The company has a market capitalization of $221.79 billion, a PE ratio of 25.54, a P/E/G ratio of 3.77 and a beta of 0.41. Amgen has a 1-year low of $269.77 and a 1-year high of $418.40.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.62 by $0.67. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The company had revenue of $10.05 billion during the quarter, compared to analysts’ expectations of $9.43 billion. During the same period last year, the company posted $6.02 EPS. Amgen’s revenue was up 9.5% on a year-over-year basis. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. On average, equities analysts predict that Amgen will post 22.73 EPS for the current fiscal year.

Amgen Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, September 11th. Stockholders of record on Friday, August 21st will be paid a $2.52 dividend. The ex-dividend date is Friday, August 21st. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.5%. Amgen’s payout ratio is currently 62.65%.

Insiders Place Their Bets

In related news, SVP Nancy A. Grygiel sold 2,970 shares of the company’s stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the completion of the sale, the senior vice president owned 7,340 shares in the company, valued at approximately $2,951,854.40. This represents a 28.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.85% of the company’s stock.

Institutional Trading of Amgen

Several hedge funds have recently bought and sold shares of AMGN. Alpine Woods Capital Investors LLC increased its position in Amgen by 8.5% in the second quarter. Alpine Woods Capital Investors LLC now owns 25,029 shares of the medical research company’s stock worth $9,064,000 after buying an additional 1,965 shares in the last quarter. Aegis Wealth Management LLC purchased a new position in shares of Amgen during the 2nd quarter valued at about $783,000. Argyle Capital Partners LLC grew its stake in shares of Amgen by 5.5% during the 2nd quarter. Argyle Capital Partners LLC now owns 4,851 shares of the medical research company’s stock valued at $1,756,000 after acquiring an additional 254 shares during the period. Quent Capital LLC increased its holdings in Amgen by 2.1% in the 2nd quarter. Quent Capital LLC now owns 6,535 shares of the medical research company’s stock worth $2,366,000 after acquiring an additional 132 shares in the last quarter. Finally, Focused Alpha LLC increased its holdings in Amgen by 9.3% in the 2nd quarter. Focused Alpha LLC now owns 3,561 shares of the medical research company’s stock worth $1,289,000 after acquiring an additional 302 shares in the last quarter. Institutional investors own 76.50% of the company’s stock.

More Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Quarterly results exceeded expectations: Amgen reported second-quarter revenue of approximately $10.05 billion, up 9.5% year over year, while adjusted earnings of $6.29 per share surpassed the $5.62 consensus estimate. Amgen Q2 2026 earnings beat, raises full-year outlook, drops AMG 513
• Positive Sentiment: Guidance was raised: Management now expects fiscal-year earnings of $22.30 to $23.50 per share, supported by growth in cardiovascular, bone-health and rare-disease medicines. The performance offset pressure in the bone-health business and the decision to discontinue obesity candidate AMG 513. Amgen Stock Climbs as Drug Growth Outruns Obesity Setback
• Positive Sentiment: Analyst targets point to additional upside: BMO Capital Markets raised its target to $450, while UBS and TD Cowen set targets of $440 and $452, respectively. Morgan Stanley, RBC, Oppenheimer and Scotiabank also indicated that Amgen’s stock could rise. BMO Capital Markets Boosts Amgen Price Target to $450
• Neutral Sentiment: Analyst sentiment remains mixed: Wells Fargo raised its target to $400 and Canaccord Genuity to $384, both below the stock’s recent trading level, while Citi maintained a Hold rating and UBS maintained a Buy rating. This suggests strong results have improved sentiment, but valuation and pipeline execution remain concerns. Citi Keeps Their Hold Rating on Amgen
• Negative Sentiment: Pipeline disappointment limits the upside case: Amgen dropped AMG 513, its obesity-drug candidate, removing a potential growth driver and leaving investors focused on the company’s existing medicines and remaining pipeline. Amgen drops AMG 513

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.